Novaremed gets FDA nod for phase 2 trial of NRD135S.E1 for PDPN

Novaremed, a clinical-stage Swiss biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to initiate its US-based Phase 2 clinical study of the novel drug candidate, NRD135S.E1, for the treatment of Painful Diabetic Peripheral Neuropathy (PDPN).